表没食子儿茶素没食子酸酯通过自噬-溶酶体途径对MPTP诱导帕金森病模型小鼠的作用

doi:10.3969/j.issn.1006-5725.2025.08.002

Abstract

Abstract:

Objective To investigate the protective effect of epigallocatechin gallate （EGCG） on 1?methyl?4?phenyl?1，2，3，6?tetrahydropyridine （MPTP）?induced Parkinson's disease model mice. Methods Twenty?eight male C57BL/6J mice aged 6 ~ 8 weeks were randomly divided into four groups： the control group， the model group， the low?dose EGCG group［25 mg/（kg·d）］， and the high?dose EGCG group［50 mg/（kg·d）］. A Parkinson's disease （PD） mouse model was established by intraperitoneal injection of MPTP at a dose of 30 mg/ （kg·d） for 7 consecutive days. The protective effect of EGCG on MPTP?induced Parkinson's model mice was analyzed through behavioral index detection and Western blot method. Results （1）In the behavioral tests， compared with the model group， the movement distance and speed of mice treated with low?and high?dose EGCG were significantly improved （both P values < 0.001）. The mice in the high?dose EGCG treatment group also showed a significant advantage in the percentage of the central path distance （P < 0.001）. （2）Compared with the control group， the deposition of α?synuclein in the model group increased significantly （P < 0.001）. Compared with the model group， both the low?and high?dose EGCG groups reduced the deposition of α?synuclein （both P < 0.001）. （3）Compared with the control group， the expression levels of Beclin 1 and LC3 proteins in the substantia nigra region of mice in the model group decreased significantly （both P < 0.001）， while the expression level of p62 protein increased significantly （P < 0.001）. After treatment with EGCG， compared with the model group， the expression levels of Beclin 1 and LC3 proteins in mice of the low?dose EGCG group increased to varying degrees （P < 0.01； P < 0.001）， and the expression level of p62 protein decreased significantly （P < 0.001）. In the high?dose EGCG group， the expression levels of Beclin 1 and LC3 proteins increased significantly （both P < 0.001）， and the expression level of p62 protein decreased significantly （P < 0.001）. Conclusion EGCG reduces alpha?synuclein deposition via the autophagy?lysosomal pathway and protects against MPTP-induced Parkinson's disease model mice.

Key words: Parkinson's disease, alpha?synuclein, epigallocatechin gallate, autophagy, autophagy?lysosome way, 1?methyl?4?phenyl?1，2，3，6?tetrahydropyridine

CLC Number:

R742.5

Xu ZHOU,Ranran LU,Fangli REN,Xiaoyu PENG,Xinling. YANG. Effect of EGCG on MPTP⁃induced Parkinson′s model mice via autophagy⁃lysosomal pathway[J]. The Journal of Practical Medicine, 2025, 41(8): 1097-1104.

Figures/Tables 6

Fig.1

Tab.1

Tab.2

Fig.2

Tab.3

Fig.3

References 39

1	PANKRATZ N， FOROUD T. Genetics of Parkinson disease［J］. Genet Med， 2007， 9（12）：801-811. doi:10.1097/gim.0b013e31815bf97c doi: 10.1097/gim.0b013e31815bf97c
2	DE LAU L M， BRETELER M M. Epidemiology of Parkinson's disease［J］. Lancet Neurol， 2006， 5（6）：525-535. doi:10.1016/s1474-4422(06)70471-9 doi: 10.1016/s1474-4422(06)70471-9
3	XILOURI M， BREKK O R， STEFANIS L. Autophagy and Alpha-Synuclein： Relevance to Parkinson's Disease and Related Synucleopathies［J］. Mov Disord， 2016，31（2）：178-192.
4	GONÇALVES P B， SODERO A C R， CORDEIRO Y. Green Tea Epigallocatechin-3-gallate （EGCG） Targeting Protein Misfolding in Drug Discovery for Neurodegenerative Diseases［J］. Biomolecules， 2021，11（5）：767. doi:10.3390/biom11050767 doi: 10.3390/biom11050767
5	GAO W， WANG Y， WANG F， et al. Ergothioneine exerts neuroprotective effects in Parkinson's disease： Targeting α-synuclein aggregation and oxidative stress［J］. Food Res Int， 2025，201：115590. doi:10.1016/j.foodres.2024.115590 doi: 10.1016/j.foodres.2024.115590
6	GADHE L， SAKUNTHALA A， MUKHERJEE S， et al. Intermediates of α-synuclein aggregation： Implications in Parkinson's disease pathogenesis［J］. Biophys Chem， 2022，281：106736. doi:10.1016/j.bpc.2021.106736 doi: 10.1016/j.bpc.2021.106736
7	DE WET S， THEART R， LOOS B. Cogs in the autophagic machine-equipped to combat dementia-prone neurodegenerative diseases［J］. Front Mol Neurosci， 2023，16：1225227. doi:10.3389/fnmol.2023.1225227 doi: 10.3389/fnmol.2023.1225227
8	LIANG Y， ZHONG G， REN M， et al. The Role of Ubiquitin-Proteasome System and Mitophagy in the Pathogenesis of Parkinson's Disease［J］. Neuromolecular Med， 2023，25（4）：471-488. doi:10.1007/s12017-023-08755-0 doi: 10.1007/s12017-023-08755-0
9	FISHMAN-JACOB T， YOUDIM M B H. A sporadic Parkinson's disease model via silencing of the ubiquitin-proteasome/E3 ligase component， SKP1A［J］. J Neural Transm （Vienna）， 2024，131（6）：675-707. doi:10.1007/s00702-023-02687-6 doi: 10.1007/s00702-023-02687-6
10	DROBNY A， BOROS F A， BALTA D， et al. Reciprocal effects of alpha-synuclein aggregation and lysosomal homeostasis in synucleinopathy models［J］. Transl Neurodegener， 2023，12（1）：31. doi:10.1186/s40035-023-00363-z doi: 10.1186/s40035-023-00363-z
11	SENKEVICH K， GAN-OR Z. Autophagy lysosomal pathway dysfunction in Parkinson's disease； evidence from human genetics［J］. Parkinsonism Relat Disord， 2020，73：60-71. doi:10.1016/j.parkreldis.2019.11.015 doi: 10.1016/j.parkreldis.2019.11.015
12	MALAR D S， PRASANTH M I， BRIMSON J M， et al. Neuroprotective Properties of Green Tea （Camellia sinensis） in Parkinson's Disease： A Review［J］. Molecules， 2020，25（17）：3926. doi:10.3390/molecules25173926 doi: 10.3390/molecules25173926
13	PICCOLI G， VOLTA M. LRRK2 along the Golgi and lysosome connection： A jamming situation［J］. Biochem Soc Trans， 2021，49（5）：2063-2072. doi:10.1042/bst20201146 doi: 10.1042/bst20201146
14	LU R， ZHOU X， ZHANG L， et al. Nrf2 Deficiency Exacerbates Parkinson's Disease by Aggravating NLRP3 Inflammasome Activation in MPTP-Induced Mouse Models and LPS-Induced BV2 Cells［J］. J Inflamm Res， 2024，17：6277-6295. doi:10.2147/jir.s478683 doi: 10.2147/jir.s478683
15	RUDENOK M M， SHADRINA M I， FILATOVA E V， et al. Expression Analysis of Genes Involved in Transport Processes in Mice with MPTP-Induced Model of Parkinson's Disease［J］. Life （Basel）， 2022，12（5）：751. doi:10.3390/life12050751 doi: 10.3390/life12050751
16	胡梦妮，张小蕾，荣臻，等. 电针对MPTP诱导帕金森病小鼠FoXO1/NLRP3通路介导神经炎症的影响［J］. 实用医学杂志， 2024， 40（11）： 1494-1499. doi:10.3969/j.issn.1006-5725.2024.11.005 doi: 10.3969/j.issn.1006-5725.2024.11.005
17	LI S， WANG Z， LIU G， et al. Neurodegenerative diseases and catechins：（-）-epigallocatechin-3-gallate is a modulator of chronic neuroinflammation and oxidative stress［J］. Front Nutr，2024，11：1425839. doi:10.3389/fnut.2024.1425839 doi: 10.3389/fnut.2024.1425839
18	逯冉冉，周旭，张利杰，等. 富马酸二甲酯减轻帕金森病模型鼠神经损伤的作用机制［J］. 中国组织工程研究， 2025，29（5）：989-994. doi:10.12307/2025.294 doi: 10.12307/2025.294
19	PRASAD E M， HUNG S Y. Behavioral Tests in Neurotoxin-Induced Animal Models of Parkinson's Disease［J］. Antioxidants （Basel）， 2020，9（10）：1007. doi:10.3390/antiox9101007 doi: 10.3390/antiox9101007
20	姜宗飞，杨文平，司锋，等. 中国帕金森病发病负担分析及预测［J］. 中华神经医学杂志， 2024，23（12）：1205-1210.
21	PAYNE A， NAHASHON S， TAKA E， et al. Epigallocatechin-3-Gallate （EGCG）： New Therapeutic Perspectives for Neuroprotection， Aging， and Neuroinflammation for the Modern Age［J］. Biomolecules， 2022，12（3）：371. doi:10.3390/biom12030371 doi: 10.3390/biom12030371
22	KIM H S， QUON M J， KIM J A. New insights into the mechanisms of polyphenols beyond antioxidant properties； lessons from the green tea polyphenol， epigallocatechin 3-gallate［J］. Redox Biol， 2014，2：187-195. doi:10.1016/j.redox.2013.12.022 doi: 10.1016/j.redox.2013.12.022
23	LIU Y， LONG Y， FANG J， et al. Advances in the Anti-Atherosclerotic Mechanisms of Epigallocatechin Gallate［J］. Nutrients， 2024，16（13）：2074. doi:10.3390/nu16132074 doi: 10.3390/nu16132074
24	SHARMA V， CHAUDHARY A A， BAWARI S， et al. Unraveling cancer progression pathways and phytochemical therapeutic strategies for its management［J］. Front Pharmacol， 2024，15：1414790. doi:10.3389/fphar.2024.1414790 doi: 10.3389/fphar.2024.1414790
25	TALIB WH， AWAJAN D， ALQUDAH A， et al. Targeting Cancer Hallmarks with Epigallocatechin Gallate （EGCG）： Mechanistic Basis and Therapeutic Targets［J］. Molecules， 2024，29（6）：1373. doi:10.3390/molecules29061373 doi: 10.3390/molecules29061373
26	CHEN Y， LIU Z， GONG Y. Neuron-immunity communication： Mechanism of neuroprotective effects in EGCG［J］. Crit Rev Food Sci Nutr， 2024，64（25）：9333-9352. doi:10.1080/10408398.2023.2212069 doi: 10.1080/10408398.2023.2212069
27	ESMAEELPANAH E， RAZAVI B M， VAHDATI HASANI F， et al. Evaluation of epigallocatechin gallate and epicatechin gallate effects on acrylamide-induced neurotoxicity in rats and cytotoxicity in PC 12 cells［J］. Drug Chem Toxicol， 2018，41（4）：441-448. doi:10.1080/01480545.2017.1381108 doi: 10.1080/01480545.2017.1381108
28	XIE X， WAN J， ZHENG X， et al. Synergistic effects of epigallocatechin gallate and l-theanine in nerve repair and regeneration by anti-amyloid damage， promoting metabolism， and nourishing nerve cells［J］. Front Nutr， 2022，9：951415. doi:10.3389/fnut.2022.951415 doi: 10.3389/fnut.2022.951415
29	NAKAMURA S， YOSHIMORI T. Autophagy and Longevity［J］. Mol Cells， 2018，41（1）：65-72.
30	LU R， ZHANG L， YANG X. Interaction between autophagy and the NLRP3 inflammasome in Alzheimer's and Parkinson's disease［J］. Front Aging Neurosci， 2022，14：1018848. doi:10.3389/fnagi.2022.1018848 doi: 10.3389/fnagi.2022.1018848
31	LI R， LU Y， ZHANG Q， et al. Piperine promotes autophagy flux by P2RX4 activation in SNCA/α-synuclein-induced Parkinson disease model［J］. Autophagy， 2022，18（3）：559-575. doi:10.1080/15548627.2021.1937897 doi: 10.1080/15548627.2021.1937897
32	XUAN F， JIAN J. Epigallocatechin gallate exerts protective effects against myocardial ischemia/reperfusion injury through the PI3K/Akt pathway-mediated inhibition of apoptosis and the restoration of the autophagic flux［J］. Int J Mol Med， 2016，38（1）：328-336. doi:10.3892/ijmm.2016.2615 doi: 10.3892/ijmm.2016.2615
33	ZHAO L， LIU S， XU J， et al. A new molecular mechanism underlying the EGCG-mediated autophagic modulation of AFP in HepG2 cells［J］. Cell Death Dis， 2017，8（11）：e3160. doi:10.1038/cddis.2017.563 doi: 10.1038/cddis.2017.563
34	ZHANG S， CAO M， FANG F. The Role of Epigallocatechin-3-Gallate in Autophagy and Endoplasmic Reticulum Stress （ERS）- Induced Apoptosis of Human Diseases［J］. Med Sci Monit， 2020，26：e924558. doi:10.12659/msm.924558 doi: 10.12659/msm.924558
35	KHAN M R， YIN X， KANG S U， et al. Enhanced mTORC1 signaling and protein synthesis in pathologic α-synuclein cellular and animal models of Parkinson's disease［J］. Sci Transl Med，2023，15（724）：eadd0499. doi:10.1126/scitranslmed.add0499 doi: 10.1126/scitranslmed.add0499
36	BAYATI A， AYOUBI R， AGUILA A， et al. Modeling Parkinson's disease pathology in human dopaminergic neurons by sequential exposure to α-synuclein fibrils and proinflammatory cytokines［J］. Nat Neurosci， 2024，27（12）：2401-2416. doi:10.1038/s41593-024-01775-4 doi: 10.1038/s41593-024-01775-4
37	ARMELI F， MENGONI B， LASKIN D L， et al. Interplay among Oxidative Stress， Autophagy， and the Endocannabinoid System in Neurodegenerative Diseases： Role of the Nrf2- p62/SQSTM1 Pathway and Nutraceutical Activation［J］. Curr Issues Mol Biol，2024，46（7）：6868-6884. doi:10.3390/cimb46070410 doi: 10.3390/cimb46070410
38	丁新玲，孙会艳，李强，等. EGCG对帕金森病神经保护作用机制研究进展［J］. 中国药理学通报， 2023，39（10）：1806-1810.
39	ZHANG Y， WU H， XU C， et al. （-）-Epigallocatechin gallate alleviates chronic unpredictable mild stress-induced depressive symptoms in mice by regulating the mTOR autophagy pathway and inhibiting NLRP3 inflammasome activation［J］. Food Sci Nutr， 2023，12（1）：459-470. doi:10.1002/fsn3.3761 doi: 10.1002/fsn3.3761

组别	数量	运动路程/m	平均速度/（mm/s）	中心路程所占百分比/%
对照组	7	69.521 ± 5.278^?	20.855 ± 1.583^?	91.211 ± 0.829^?
模型组	7	21.711 ± 10.674	6.514 ± 3.202	85.779 ± 3.065
低剂量组	7	55.740 ± 4.234^?	16.722 ± 1.270^?	87.258 ± 1.762
高剂量组	7	62.024 ± 6.977^?	18.607 ± 2.093^?	90.307 ± 1.440^?
F值		59.95	59.95	11.92
P值		< 0.001	< 0.001	< 0.001

组别	α-syn蛋白相对表达量
对照组	0.626 ± 0.009^*
模型组	1.339 ± 0.016
低剂量组	0.869 ± 0.006^*
高剂量组	0.760 ± 0.024^*
F值	1 228
P值	< 0.001

组别	Beclin 1蛋白相对表的量	LC3蛋白相对表的量	p62蛋白相对表的量
对照组	1.476 ± 0.047^***	1.614 ± 0.025^***	0.883 ± 0.883^***
模型组	0.880 ± 0.010	0.620 ± 0.016	1.312 ± 0.026
低剂量组	1.010 ± 0.020^**	1.168 ± 0.022^***	1.077 ± 0.016^***
高剂量组	1.184 ± 0.015^***	3.489 ± 0.072^***	0.699 ± 0.070^***
F值	270.4	284.4	275.6
P值	< 0.001	< 0.001	< 0.001

[1]	Zhizhou XIAO,Ying HUANG,Huawei. BIAN. To investigate the effect of aloperine on bone metabolism in osteoporotic mice based on autophagy and apoptosis mediated by Wnt/β⁃catenin signaling pathway [J]. The Journal of Practical Medicine, 2025, 41(4): 500-508.
[2]	Fangming WANG,Wenxuan SHANG,Jingwen ZHANG,Yingxiao JI,Litao. LI. Research advances on the regulation of microglia polarization by autophagy in ischemic stroke [J]. The Journal of Practical Medicine, 2024, 40(9): 1324-1330.
[3]	Lulu CHEN,Meng LUO,Kaiqi SU,Jing GAO,Xiaodong. FENG. Research progress of the endoplasmic reticulum⁃mitochondrial interactions in post⁃stroke cognitive impairment [J]. The Journal of Practical Medicine, 2024, 40(7): 1023-1028.
[4]	Ying ZHOU,Dajun JIANG,Yong TIAN,Yongxiang GU,Guohui. YANG. Inhibition of TRAF6 ameliorates myocardial inflammatory injury and cardiac dysfunction via regulating cardiomyocyte inflammation in sepsis mice [J]. The Journal of Practical Medicine, 2024, 40(5): 608-614.
[5]	Sumei YU,Yuyue ZHANG,Liwen MA,Yuanjun KUANG,Qingning CHANG,Min KONG,ZHANG Huiping ZHANGx. Effect of miR⁃15a⁃5p on autophagy of placental trophoblasts in preeclampsia [J]. The Journal of Practical Medicine, 2024, 40(12): 1631-1636.
[6]	Juan LIU,Yanjie LI,Hewei QIN,Luyao MA,Nannan ZHAO,Huimin. DING. Mechanism of action of dysregulated mitochondrial quality control system mediating Parkinson′s disease [J]. The Journal of Practical Medicine, 2024, 40(11): 1479-1482.
[7]	Xue MA,Shihui. ZHOU. Role and potential mechanisms of p62/SQSTM1 on migration and metastasis of non⁃small cell lung cancer [J]. The Journal of Practical Medicine, 2024, 40(1): 13-18.
[8]	Tao WU,Suming DING,Chang ZHAN,Wenwen CUI,Weihua. TANG. Changes in serum autophagy markers in infants with retinopathy of prematurity and the clinical value [J]. The Journal of Practical Medicine, 2024, 40(1): 79-84.
[9]	LI Xiaoping, ZHOU Hongjian, GAO Fangfang, LI Wei.. Tspan1 antagonizes oxaliplatin⁃induced apoptosis in colorectal cancer cells by inducing cellular autophagy [J]. The Journal of Practical Medicine, 2023, 39(9): 1072-1078.
[10]	GE Liang, LENG Yufang, ZHANG Peng, DU Lifang, HAN Xudong.. Effects of dexmedetomidine on oxidative stress and inflammation levels in prostaglandin induced asphyxiat⁃ ed offspring by activating PI3K/AKT signaling pathway and its role in brain protection [J]. The Journal of Practical Medicine, 2023, 39(6): 688-695.
[11]	QU Xiaoxiao, QIAO Qing⁃ yang, CHEN Ning, SONG Tongyang, LI Yu, LIU Shuyi.. Effect of autophagy on steroid ⁃induced osteonecrosis of femoral head in rats [J]. The Journal of Practical Medicine, 2023, 39(3): 285-297.
[12]	WANG Xiaoyun, TANG Hongmei, WANG Xing, MA Ning, LI Yuejiao, YUAN Xiefang, XU Guofeng, ZHANG Yun.. SiO2 increases MUC5AC expression by regulating autophagy in human airway epithelia cells [J]. The Journal of Practical Medicine, 2023, 39(3): 303-308.
[13]	Siyuan XIONG,Lu WANG,Junjie TIAN,Yang GU,Yajing MA,Ketao MA,Yingying ZHANG,Xinzhi. LI. Role of Cx43 in ox⁃LDL induced RAW264.7 autophagy [J]. The Journal of Practical Medicine, 2023, 39(20): 2572-2578.
[14]	Ruijuan WANG,Chao LI,Lijuan DUAN,Miao SHANG,Ruyu. YANG. Impacts of chlorprothixene on autophagy and apoptosis in human acute myeloid leukemia cells by regulating Akt/mTOR pathway [J]. The Journal of Practical Medicine, 2023, 39(20): 2584-2590.
[15]	FU Xuefeng, LOU Siyu, PENG Zhangli.. Mycobacterium tuberculosis Rv3737 suppresses macrophage autophagy to enhance bacterial survival in macrophages [J]. The Journal of Practical Medicine, 2023, 39(2): 198-203.

Effect of EGCG on MPTP⁃induced Parkinson′s model mice via autophagy⁃lysosomal pathway

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 6

References 39

Related Articles 15

Recommended Articles

Metrics

Comments